Mogamulizumab - induced bone granuloma

Joint Bone Spine. 2024 Sep 25:105782. doi: 10.1016/j.jbspin.2024.105782. Online ahead of print.

¹ University of Lille, INSERM U 1189, Dermatology Department, Claude Huriez Hospital, Lille, France. Electronic address: [email protected].
² Rhumatology Department, Salengro Hospital, Lille, France.
³ University of Lille, INSERM U 1189, Dermatology Department, Claude Huriez Hospital, Lille, France.
⁴ Internal Medicine Department, Claude Huriez Hospital, Lille, France.
⁵ Anathomopathology Department, pathology institute, Lille, France.
⁶ Hematology Department, Claude Huriez Hospital, Lille, France.
⁷ University of Lille, INSERM U 1189, Dermatology Department, Claude Huriez Hospital, Lille, France; Dermatology Department, Roubaix, France.
⁸ University of Lille, INSERM U 1189, Dermatology Department, Claude Huriez Hospital, Lille, France; Dermatology Department, Douai, France.

No abstract available

Keywords: Adverse event; Bone granuloma; CCR4; Mogamulizumab; Mogamulizumab associated rash; Mycosis Fungoides; PTCL; Sezary Syndrome.

Publication types